Safety and Effectiveness of a Novel Liposomal Intra-Articular Lubricant in Symptomatic Knee Osteoarthritis: A First-in-Human Study
Journal of Clinical Medicine · 18.11.2024 · 13 (22) · 6956
DOI: 10.3390/jcm13226956 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.11.2024. Verfasst von Shai Shemesh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Assuta Ashdod University Hospital, Ben-Gurion University of the Negev, Ashdod 7747629, Israel. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Liposphere LTD, Liposphere Ltd..
Abstract (Originalsprache)
Background/Objectives: Osteoarthritis (OA) is a common disease that affects almost half the population at some point in their lives, causing pain and decreased functional capacity. New conservative treatment modalities are being proposed to provide symptomatic relief and delay surgical intervention. This study aimed at evaluating the safety of the novel liposomal boundary lubricant, injected intra-articularly in patients with moderate knee OA. Additionally, the effect on the functionality and life quality was assessed.
Methods
Eighteen of the twenty screened subjects met inclusion criteria and were enrolled in the study. After receiving a single IA injection of AqueousJoint, patients were prospectively evaluated at baseline and at 2, 4, 8, 12, and 26 weeks. Numeric Pain Rating Scale (NRS), Knee injury and Osteoarthritis Outcome Score (KOOS), Short Form Health Survey (SF12) and range of motion were also recorded.
Results
The final analysis was conducted on 18 subjects. No adverse events related to the investigational product were observed in the study. No serious adverse events were observed at all. A significant decrease in pain was demonstrated at all time points vs. baseline (Friedman X2 = 35.08, p < 0.001). Significant improvement was demonstrated in KOOS pain, symptoms, sports, and ADL subscales (p < 0.001).
Conclusions
Despite a relatively small sample, it was demonstrated that single IA AqueousJoint injection is a safe procedure, resulting in significant pain reduction, higher ADL score, and higher KOOS sport scores. The effects lasted up to 6 months.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Assuta Ashdod University Hospital, Ben-Gurion University of the Negev, Ashdod 7747629, Israel.
- Liposphere Ltd., Givat-Shmuel 5400804, Israel.
- Division of Orthopedics, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
- Adelson School of Medicine, Ariel University, Ariel 4070000, Israel.
- Sanz Medical Center, Laniado Hospital, Ariel University, Ariel 4070000, Israel.
- Assuta Hospital Ramat Hachayal, Tel Aviv 6971028, Israel.
ORCID-Profile: Shai Shemesh, Yaniv Warschawski, Haggai Schermann, Michael Drexler
Förderung
- Liposphere LTD
- Liposphere Ltd.
Zitieren
APA
Shemesh, S., Dolkart, O., Goldberg, R., Jahn, S., Khoury, A., Warschawski, Y., Schermann, H., Salai, M., Agar, G., & Drexler, M. (2024). Safety and Effectiveness of a Novel Liposomal Intra-Articular Lubricant in Symptomatic Knee Osteoarthritis: A First-in-Human Study. Journal of Clinical Medicine, 13(22), 6956. https://doi.org/10.3390/jcm13226956
Vancouver
Shemesh S, Dolkart O, Goldberg R, Jahn S, Khoury A, Warschawski Y, et al. Safety and Effectiveness of a Novel Liposomal Intra-Articular Lubricant in Symptomatic Knee Osteoarthritis: A First-in-Human Study. Journal of Clinical Medicine. 2024;13(22):6956. doi:10.3390/jcm13226956
BibTeX
@article{Shemesh2024,
author = {Shemesh, Shai and Dolkart, Oleg and Goldberg, Ronit and Jahn, Sabrina and Khoury, Amal and Warschawski, Yaniv and Schermann, Haggai and Salai, Moshe and Agar, Gaby and Drexler, Michael},
title = {Safety and Effectiveness of a Novel Liposomal Intra-Articular Lubricant in Symptomatic Knee Osteoarthritis: A First-in-Human Study},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {22},
pages = {6956},
doi = {10.3390/jcm13226956}
}
EUVIMED